Introduction
Cancer is a disease commonly characterized by genomic instability (Lengauer et al., 1998) . To protect the genome, eukaryotic cells have evolved signalling pathways that arrest cell cycle progression in response to DNA damage (the DNA damage checkpoints) and facilitate DNA repair or, in case of too severe damage, eliminate such potentially hazardous cells through apoptosis (Zhou and Elledge, 2000; Bartek and Lukas, 2001a, b; Hoeijmakers, 2001; Rouse and Jackson, 2002) . The DNA damage checkpoint is initiated by activation of the ATM and ATR kinases, which signal to arrest the cell cycle and induce DNA repair or apoptosis by phosphorylating several functionally different substrates including p53, BRCA1, Nbs1, FANCD2, Chk1, and Chk2 (May and May, 1999; Abraham, 2001; Bartek et al., 2001; D'Amours and Jackson, 2002; Taniguchi et al., 2002; Shiloh, 2003; Srensen et al., 2003) . The connection between cancer and the DNA damage response is substantiated by ATM, p53, BRCA1, Nbs1, FANCD2, and Chk2 alterations leading to increased cancer susceptibility (Varley et al., 1997; Rotman and Shiloh, 1999; Meijers-Heijboer et al., 2002; Moynahan, 2002; Tauchi et al., 2002; Vahteristo et al., 2002; Shiloh, 2003) , and by inactivating p53 mutations, which are the most common genetic alteration found in human cancers (May and May, 1999; Soussi and Beroud, 2001) .
In response to different DNA-damaging stimuli such as UV light or ionizing radiation (IR), the checkpoint kinases Chk1 and Chk2 phosphorylate Cdc25A, leading to accelerated turnover of Cdc25A via ubiquitindependent, proteasome-mediated proteolysis. The resulting depletion of Cdc25A, a phosphatase needed for removal of inhibitory phosphorylations from the cyclindependent kinase Cdk2, leads to inhibition of cyclin E(A)/Cdk2 complexes and cell cycle arrest Falck et al., 2001) . This checkpoint branch operates at the G 1 /S transition, and throughout S and G 2 phases, consistent with the cell cycle-dependent, c-Myc-and E2F-stimulated expression of Cdc25A from late G 1 (Jinno et al., 1994; Galaktionov et al., 1996; Vigo et al., 1999) , and phosphorylation-dependent stabilization leading to nondegradable Cdc25A in mitosis (Mailand et al., 2002) . Accordingly, flexible adjustments of Cdc25A protein turnover contribute to regulation of G 1 /S, intra-S, and G 2 checkpoints Falck et al., 2001; Mailand et al., 2002; Srensen et al., 2003) .
Cdc25A, a member of the cell cycle-regulatory Cdc25 phosphatase family (Nilsson and Hoffmann, 2000; Mondesert et al., 2002) , is an established protooncogene, as its overexpression cooperates with H-RAS G12V or loss of pRb to transform rodent fibroblasts (Galaktionov et al., 1995) . Moreover, a high frequency of Cdc25A overexpression was found in several types of human cancer including carcinomas of the breast, oesophagus, head and neck, and lung (Gasparotto et al., 1997; Wu et al., 1998; Cangi et al., 2000; Nishioka et al., 2001) . In addition, correlations between Cdc25A overexpression and both clinically aggressive behaviour of tumors and poor survival of patients have been reported (Cangi et al., 2000; Nishioka et al., 2001) . As most of these studies were based on semiquantitative assessment of mRNA expression, little is known about the changes of Cdc25A protein levels in cancer cells, and their impact on its phosphatase activity and the checkpoint response.
In the present study, we aimed to address these issues by investigating a representative panel of human breast cancer cell lines. We found elevated Cdc25A protein levels and phosphatase activities in the majority of the studied cell lines, some of which also showed impaired Cdc25A responses to checkpoint activation and radiation hypersensitivity. Moreover, we found evidence that deregulation of Cdc25A levels mainly occurs on the post-transcriptional level, with increased protein stability being an important mode of upregulation.
Results

Upregulation of Cdc25A in human breast cancer cell lines
As Cdc25A mRNA has been reported to be frequently overexpressed in breast cancer (Cangi et al., 2000) , we chose 15 human breast cancer cell lines for detailed evaluation of the abundance of Cdc25A protein and its enzymatic activity. As a control, we included a normal human mammary epithelial cell line (HME1) immortalized by the telomerase catalytic subunit (Jiang et al., 1999) .
It has been repeatedly shown that the Cdc25A phosphatase is regulated by modulating its protein stability, and its biological effects are determined by its protein abundance (Mailand et al., , 2002 Falck et al., 2001; Donzelli et al., 2002) . Therefore, we examined Cdc25A protein abundance in exponentially growing, unstressed cells by immunoblotting, and reproducibly observed elevated Cdc25A protein levels in most breast cancer cell lines when compared with HME1 cells (Figure 1a ). Quantification using a luminescent image analyser revealed that in six out of 15 breast cancer cell lines, the Cdc25A protein level was more than 10 times higher than in HME1, and most of the remaining cancer cell lines still showed Cdc25A elevation to a variable but detectable degree ( Figure 1b , Table 1 ).
As Cdc25A expression is cell cycle dependent, one could argue that Cdc25A protein overabundance in exponentially growing cancer cells might reflect differences in the cell cycle distribution and E2F-dependent transcription. To address these issues, we used another E2F-responsive cell cycle regulator, cyclin A, and the Mcm7 protein (which does not oscillate during the cell cycle) as internal controls to standardize Cdc25A quantification. This analysis showed that cell cycle distribution had little if any effect on the quantification of the results and could not explain the observed Cdc25A overabundance (Figure 1a, b) . Furthermore, direct cell cycle analysis of exponentially growing cells revealed combined S/G 2 /M fractions (the cell cycle phases in which Cdc25A is physiologically expressed) in the range of 19-37% in the cancer cell lines (with only one exception, the SV40-transformed cell line HBL100, with 52% cells in S/G 2 /M), compared to 24% in HME1 cells (Figure 2 and data not shown, Table 1 ). These differences were clearly too small to explain the far more pronounced differences in Cdc25A protein abundance. Taken together, our results indicate that the Cdc25A protein is upregulated in a large proportion of the studied breast cancer cell lines.
Since the quantitative accuracy of immunoblotting for a low-abundance protein like Cdc25A is inevitably limited, we sought to verify our data by assaying the activity of immunoprecipitated Cdc25A. Indeed, we found that the Cdc25A-associated phosphatase activity in breast cancer cells was up to nine times higher than in HME1 cells (Figure 3a , b, Table 1 ). Moreover, there was a strong correlation between high phosphatase activities and elevated protein levels of Cdc25A (Table 1 ): a more than 10-fold elevation of Cdc25A protein together with a more than fourfold elevation of its phosphatase activity was found in five cell lines (MCF7, AU565, DU4475, HBL100, ZR75-1), while three cell lines (MDA468, HCC1569, HCC1395) showed Cdc25A upregulation to a lesser but still significant degree (5-10-fold higher protein and two to three times increased phosphatase activities, respectively). In contrast, Cdc25A was rather low in five cell lines (protein levels less than fivefold and phosphatase activities less than twofold elevated, respectively), and only two of the 15 cell lines (BT549 and PMC42) did not show such a close correlation between protein and phosphatase activity levels. It should also be noted that the differences in phosphatase activities between the cell lines were clearly too large to be solely explained by the rather small differences in cell cycle distribution (see Figure 2 and Table 1 ). In summary, immunoblots and phosphatase assays revealed concordant results to demonstrate a specific upregulation of the Cdc25A phosphatase in a large proportion of the studied breast cancer cell lines. Furthermore, we sought to verify our finding by immunocytochemistry of cells of selected cell lines grown on glass coverslips. HME1 cells revealed very weak signal of Cdc25A ( Figure 4a ) consistent with the low amount of this rate-limiting phosphatase in diploid cells (see Figures 1 and 3 ). The BT549 cell line, which had a moderately increased Cdc25A protein abundance and phosphatase activity (see Figures 1 and 3 ), also showed a weak nuclear staining pattern of Cdc25A ( Figure 4b ). In contrast, consistent with the more pronounced Cdc25A upregulation found in immunoblots and phosphatase assays, MCF7 cells displayed a variable, predominantly nuclear Cdc25A staining pattern (Figure 4c ), which was clearly stronger than in HME1 and BT549 cells stained in parallel (Figure 4a-c) . Moreover, in AU565 cells, where Cdc25A protein levels and activity were very high (see Figures 1 and 3 ), immunocytochemistry revealed a high abundance of predominantly nuclear Cdc25A (Figure 4d ). ZR75-1, another cell line with exceptionally high Cdc25A, showed a staining pattern similar to AU565 (data not shown). In conclusion, our immunocytochemical findings provide not only another verification of the specific upregulation of Cdc25A in these breast cancer cell lines, but also indicate that this upregulation can be tested by immunocyto-and/or -histochemistry.
Cdc25A upregulation occurs on the post-transcriptional level
As the abundance of Cdc25A is normally regulated via its protein turnover, we speculated that aberrantly enhanced protein stability might play a role in this cancer-associated Cdc25A upregulation. This would imply post-transcriptional rather than transcriptional upregulation, a notion that was examined by quantification of Cdc25A messenger RNA (mRNA) through analysis of complementary DNA (cDNA) amplification Table 1 ). This moderate overexpression of Cdc25A mRNA was independent of cell cycle distribution, as evidenced by normalization against cyclin A analysed under identical conditions ( Figure 5 ). Hence, in most cell lines, the extent of Cdc25A mRNA overexpression was clearly too small to explain the far more pronounced Cdc25A protein upregulation. Moreover, mRNA and protein levels were not proportional to each other, as demonstrated by normal Cdc25A mRNA expression in AU565 (Figure 5 ), the cell line with the highest Cdc25A protein abundance (see Figure 1b) . We conclude that in the studied breast cancer cell lines, mRNA overexpression is a relatively minor contributor to the elevated protein levels of Cdc25A, while the major mechanism of Cdc25A upregulation appears to be defective control on the post-transcriptional level. Figure 5 The degree of Cdc25A protein upregulation does not correlate with mRNA overexpression. Cdc25A mRNA levels were quantified using real-time PCR. Three independent experiments were carried out for each primer set. Each experiment included all cell lines, and HME1 was defined as standard with the value 1. The Cdc25A mRNA quantities are given as ratios relative to the housekeeping gene porphobilinogen deaminase (PBGD; black bars) and cyclin A (open bars), respectively (mean7s.d.)
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Impaired Cdc25A response to checkpoint activation in a subset of cdc25A-overexpressing breast cancer cell lines
To test whether the observed upregulation of Cdc25A is associated with an impaired DNA damage checkpoint, we assayed the Cdc25A response to checkpoint activation by 10 Gy of g-irradiation. Both Cdc25A protein levels and phosphatase activities 1 h after irradiation were evaluated and compared to undamaged cells. In this assay, the normal response represented by HME1 was a downregulation of Cdc25A phosphatase activity to approximately 30% of that measured in undamaged cells, paralleled by a similar degree of Cdc25A protein reduction ( Figure 6 ). While most of the studied cancer cell lines were proficient in this response, the radiationinduced downregulation of Cdc25A was reduced to being absent in HCC1395, ZR75-1, DU4475, and AU565 cells ( Figure 6 and data not shown, Table 1 ). Notably, due to high starting levels (see Figure 3 ), even some cell lines capable of downregulating Cdc25A still contained higher-than-normal levels and activities of Cdc25A after g-irradiation. This was particularly the case in MCF7 and HBL100 cells (data not shown). In HCC1395, ZR75-1, DU4475, and AU565 cells, Cdc25A protein levels and phosphatase activities after girradiation were, in several independent experiments, consistently in the range of 50-100% compared to nonirradiated controls (Figure 6 ). Importantly, we could exclude oversaturation of the phosphatase assay as an explanation for the lack of differences between damaged and undamaged cells, as variation of protein inputs revealed linearity of the assay within the range of measured activities (data not shown). Similarly, the rather weak correlation between Cdc25A upregulation and impaired Cdc25A responses to IR (Table 1) argues that these impaired Cdc25A responses may not simply result from highly upregulated Cdc25A levels oversaturating the proteolysis machinery. For example, an impaired response was observed in HCC1395 cells with intermediate levels of Cdc25A, in contrast to relatively efficient downregulation of high Cdc25A levels in MCF7 and HBL100 cells.
Furthermore, activities of the cell cycle-stimulating kinase Cdk2, the immediate downstream target of Cdc25A, were normally downregulated 1 h after IR in HME1, BT20, and MCF7 cells. In contrast, Cdk2 activity remained virtually unchanged after g-irradiation in HCC1395 and DU4475, while it was, under these conditions, still downregulated in ZR75-1 and AU565 cells (Figure 6 ). These results suggest a complete deficiency of this DNA damage checkpoint branch in HCC1395 and DU4475, in contrast to a partial deficiency in AU565 and ZR75-1 cells, where so far unexplored redundant mechanisms might downregulate Cdk2 activity under the tested conditions. We conclude that in addition to Cdc25A upregulation, the Cdc25A-mediated DNA damage checkpoint is abrogated at least in a subset of the studied cancer cell lines. Moreover, even in cell lines with intact Cdc25A responses, but high starting levels of Cdc25A, the Cdc25A activity remained above the normal range after g-irradiation, a phenomenon that, under some conditions such as different radiation doses, might alter the integrity and/or the velocity of the checkpoint response.
Increased protein stability contributes to cancer-associated Cdc25A upregulation Next, we tested whether regulation of Cdc25A protein turnover by the ubiquitin-proteasome pathway might explain the increased levels of Cdc25A. Unfortunately, assessment of turnover of a low-abundance protein whose stability is regulated after DNA damage like Cdc25A is technically limited. As the 35 S-labelling and methionine pulse-chase assay appeared not to be sensitive enough for the studied cell lines (data not shown), and the use of 35 S may lead to checkpoint activation by itself, we measured the half-life of endogenous Cdc25A after cycloheximide-induced inhibition of protein translation both in unirradiated and girradiated cells of selected cell lines. The half-life of endogenous Cdc25A in exponentially growing, unstressed cells has been reported to be 20 min or less in U2OS (Mailand et al., 2002) and HeLa cells (Donzelli et al., 2002) . Similarly, we found that in MCF7 cells, the Cdc25A half-life was about 15 min, with further destabilization in response to 10 Gy of g-irradiation (Figure 7) . In contrast, Cdc25A protein was more stable in AU565, with an estimated half-life of 30-60 min in undamaged cells (Figure 7) . Comparison of these data to the protein levels (see Figure 1b) revealed the dependence of Cdc25A upregulation on its stabilization. In response to IR, Cdc25A protein turnover was still accelerated in AU565 cells (Figure 7) . In contrast, ZR75-1 cells displayed not only a prolonged Cdc25A half-life of about 30 min under unstressed conditions (Figure 7) , consistent with its high protein level (see Figure 1b ), but also a diminished response in terms of Cdc25A protein turnover after g-irradiation (Figure 7 ). This inability to normally accelerate the Cdc25A proteolysis was consistent with the diminished radiation response of the Cdc25A protein level and phosphatase activity in ZR75-1 cells (see Figure 6 ). Similarly, although the half-life estimation was difficult for HCC1395 due to the low starting protein level, the available data indicated that there was virtually no difference between Cdc25A stability in undamaged and damaged cells of this cell line (data not shown), again consistent with the lack of Cdc25A response to IR in HCC1395 cells (see Figure 6 ). In summary, these half-life measurements demonstrate that increased Cdc25A protein stability correlates with Cdc25A protein upregulation in the tested cell lines. Taken together with the lack of a correlation between mRNA and protein levels (see Table 1 ), these data indicate that increased protein stability is likely to be an important factor determining the cancer-associated upregulation of Cdc25A.
Cdc25A deregulation correlates with radiation hypersensitivity
Finally, we sought to find biological correlates of the demonstrated Cdc25A deregulation in breast cancer cell lines. We chose five cell lines for evaluation of their clonogenic survival after different doses of IR (Figure 8 ). There were no significant differences in survival rates after 2, 4, or 6 Gy of IR between control HME1 and BT20 cells, which have low, normally regulated Cdc25A levels. MCF7 cells, which have higher but still normally regulated Cdc25A levels, were equally sensitive to the given doses of IR (Figure 8 ). In contrast, both AU565 and ZR75-1, cell lines with highly upregulated Cdc25A and deficient Cdc25A responses to radiation-induced checkpoint activation (see Figures 1 and 6) , were hypersensitive to IR with significantly reduced survival after 2, 4, and 6 Gy of g-irradiation in ZR75-1, and after 6 Gy in AU565 cells (Figure 8 ). This correlation between Cdc25A deregulation and radiosensitivity indicates that, indeed, the deregulation of the Cdc25A-mediated 
Discussion
In the present study, we demonstrate that the protein levels of Cdc25A are upregulated in the majority of the 15 tested human breast cancer cell lines. The elevated protein abundance correlated with enhanced phosphatase activity of Cdc25A. The extent of upregulation of the phosphatase activities appeared generally somewhat lower than that of Cdc25A protein levels. This might reflect differences in the sensitivity and specificity of the antibodies used for phosphatase assays and immunoblotting, respectively. On the other hand, it is tempting to speculate about the existence of some so far unknown feedback mechanisms possibly acting against excessively high Cdc25A activity. Such counter-balancing mechanisms may have evolved to prevent deleterious effects of the vast excess of Cdc25A activity on the viability of the cells. Nevertheless, the generally good correlation between protein levels and phosphatase activities demonstrates a biologically relevant, specific upregulation of Cdc25A in a high proportion of the tested breast cancer cell lines. Our data are in agreement with previous clinical studies that reported frequent overexpression of Cdc25A in several types of cancer (Gasparotto et al., 1997; Wu et al., 1998; Cangi et al., 2000; Nishioka et al., 2001 ). However, most clinical studies were restricted to Cdc25A mRNA detection, while our data indicate that, apart from moderate cancer-associated overexpression of Cdc25A mRNA, post-transcriptional aberrations also seem to contribute to the observed overabundance of the Cdc25A protein. Notably, the only study so far assessing the Cdc25A protein did not only reveal that Cdc25A was frequently overabundant in oesophagus carcinoma, but also that it was associated with deeper tumour invasion, lymph node metastasis, tumour size, and poor survival (Nishioka et al., 2001) . Therefore, Cdc25A protein might turn out to be an important prognostic marker in many types of cancer.
By measuring the half-life of the Cdc25A protein, we directly demonstrated, for the first time, that its stability is increased in cell lines with high protein levels. Although we could only test a limited number of cell lines, the good correlation between half-life and protein levels indicates that increased stability might be a common mechanism of Cdc25A upregulation. This notion is also plausible given the mechanistic data on Cdc25A regulation via its ubiquitin-proteasomemediated turnover, both in the undisturbed cell cycle (Donzelli et al., 2002; Mailand et al., 2002) and in response to checkpoint activation Falck et al., 2001) . As this is the only known posttranscriptional mechanism to regulate Cdc25A, and our data excluded that high Cdc25A protein levels could be solely attributed to transcriptional upregulation, we propose that high Cdc25A levels resulting from aberrantly enhanced protein stability might be common not only in breast cancer, but possibly also in other types of cancer. To rigorously validate this prediction is a challenge for future clinical studies.
To assess the biological relevance and consequences of elevated Cdc25A levels, we tested the Cdc25A response to checkpoint activation by g-irradiation in our cell lines, in some cases complemented by half-life measurements. We found that some cell lines were deficient in this response to g-irradiation, and that this deficiency was not strictly dependent on the Cdc25A protein level. Thus, this defective control of protein turnover cannot be explained by oversaturation of the ubiquitin-proteasome machinery due to high Cdc25A protein levels. We also tested whether this defective Cdc25A response led to downstream checkpoint deficiency on the level of Cdk2, which was the case for two of the four cell lines examined. We conclude that the detected abnormalities provide good evidence that the Cdc25A-mediated DNA damage checkpoint is abrogated at least in a subset of the studied breast cancer cell lines. Moreover, we demonstrated a strong correlation between this checkpoint abrogation and hypersensitivity to IR, indicating that breast cancer-associated deregulation of the Cdc25A-mediated DNA damage checkpoint may lead to biologically relevant cellular defects, which may undermine cellular responses to genotoxic stress.
Based on our present findings, it is attractive to speculate that Cdc25A, a central mediator of DNA damage-induced checkpoint pathways, may be deregulated in cancer cells via several distinct mechanisms including the control of its stability. These abnormalities Cdc25A deregulation in breast cancer cells H Löffler et al may occur at different steps of Cdc25A protein turnover regulation and, together with overexpression of Cdc25A mRNA, they may provide selective growth advantages during the multistep cancer development. Such advantages may include a reduced dependency on growth factors in the undisturbed cell cycle through continuously high Cdc25A activity. In addition, persistently high Cdc25A activity uncoupled from checkpoint signalling may lead to genomic instability through promoting illegitimate cell cycle progression before the genome integrity is restored. This potential role of Cdc25A in oncogenesis should inspire further research on the mechanisms of cancer-associated Cdc25A deregulation, which may include abrogated checkpoint signalling pathways or deficiencies in ubiquitinmediated proteolysis. It has been previously reported that overexpression of Cdc25A causes radioresistant DNA synthesis, accumulation of DNA damage and decreased survival after DNA damage Falck et al., 2001) . Data presented here extend these findings by showing a correlation between Cdc25A deregulation and radiation hypersensitivity in breast cancer cells. Collectively, these studies may inspire broader investigation of the biological consequences of cancer-associated Cdc25A deregulation including the impact of deregulated Cdc25A turnover on cellular responses to various cancer treatment modalities. Finally, the overabundance of Cdc25A may assist future diagnostic and prognostic classification of cancer, and possibly provide a basis for developing novel strategies to combat deregulated proliferation of cancer cells.
Materials and methods
Cell culture, flow cytometry, protein stability measurements and clonogenic survival assays HME1 cells (BD Biosciences Clontech) were cultured in Clonetics mammary epithelial cell growth medium (Cambrex). All other cell lines were cultured in DMEM supplemented with 10% fetal calf serum (Gibco) and antibiotics. To generate DNA damage, subconfluent dishes were subjected to 10 Gy of g-irradiation delivered by an X-ray generator (RT100; Philips Medico; 100 kV, 8 mA, dose rate 0.92 Gy/min; or HF160; Pantak; 150 kV, 15 mA, dose rate 2.18 Gy/min), and lysates of damaged cells as well as undamaged controls were collected after 1 h. Cells cultured in parallel were trypsinized and stained with propidium iodide in order to determine the DNA content using a FACSCalibur flow cytometer (BD Biosciences), and cell cycle distributions were calculated by the ModFit LT software (Verity Software House). Protein stability was measured by incubation in medium containing 50 mg/ml cycloheximide for the time indicated in the figure; immediately before addition of cycloheximide, samples were g-irradiated with 10 Gy when indicated. Clonogenic survival was assayed by plating 500-6000 cells (depending on cell type and radiation dose to yield 50-100 colonies per dish) on 6 cm dishes in triplicate. Cells were irradiated after 18 h, cultivated for 2 weeks, and stained with crystal violet. Survival fractions were calculated as the quotients of average cloning efficiencies (number of viable colonies divided by cell input) of irradiated to nonirradiated cells.
Antibodies, immunochemical methods, kinase and phosphatase assays
We used mouse monoclonal antibodies to Mcm7 (DCS-141; Srensen et al., 2000) , Cdc25A (F6; Santa Cruz), cyclin A (Ab-3; Oncogene), Cdk7 (MO-1; Tassan et al., 1994) for immunoblots and immunocytochemistry, and to Cdc25A (DCS-124; Mailand et al., 2000) and cyclin B1 (sc-245; Santa Cruz) for immunoprecipitations. Cdk2 was immunoprecipitated using a polyclonal rabbit antibody (M2; Santa Cruz). Protein extracts for immunoblots and immunoprecipitations were made by lysis of cells in an appropriate volume of lysis buffer (50 mm N-2-hydroxyethylpiperazine-N 0 -2-ethanesulphonic acid (HEPES; pH 7.5), 150 mm NaCl, 1 mm EDTA, 2.5 mm EGTA, 10% glycerol, 0.1% Tween 20, 10 mm b-glycerophosphate, 1 mm NaF, 1 mm dithiothreitol, 0.1 mm sodium orthovanadate, 25 mg/ml phenyl-methyl-sulphonyl-fluoride, 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin), mechanical homogenization, and collection of the supernatant after 10 min centrifugation at 20 000 Â g. A measure of 100 mg of protein per sample was used for immunoblotting as described previously (Lukas et al., 1995) . Kinase activity of Cdk2 immunoprecipitated from 250 mg of protein per reaction was determined following a standard protocol using histone H1 as substrate (Santoni-Rugiu et al., 2000) . Phosphatase activity of Cdc25A, immunoprecipitated from 1 mg of protein per reaction, was determined following a published method , which assays the ability of Cdc25A to activate cyclin B1-Cdc2 immunoprecipitated in the inactive state from U2OS cells treated with doxorubicin; after incubation with Cdc25A, the activity of cyclin B1-Cdc2 was evaluated using histone H1 as substrate. Protein levels, kinase and phosphatase activities were quantified using the ImageGauge software (Fuji) connected to an LAS-1000 luminescent image analyser (Fuji) for immunoblots, or to a FLA-3000 fluorescent image analyser (Fuji) for kinase and phosphatase assays. Immunocytochemistry for Cdc25A, on cells cultured on glass coverslips and fixed for 10 min in buffered formalin, was done using the sensitive immunoperoxidase-based Vectastain Elite kit (Vector Laboratories, Glostrup, Denmark) and metal enhancement as described (Bartkova et al., 1994) ; nuclear counterstaining was omitted for photography.
Real-time PCR
Total RNA was isolated from exponentially growing cells using the RNAqueous kit (Ambion). cDNA was generated from 1 mg RNA per reaction using Moloney murine leukaemia virus reverse transcriptase (Stratagene) following the manufacturer's suggestions. The PCR mixture containing 0.3 ml of undiluted or diluted cDNA reactant, 0.5 mm of each primer, and 3 mm MgCl 2 in a final volume of 10 ml was prepared using the LightCycler-Fast Start DNA Master SYBR Green I kit (Roche). The PCR in a LightCycler (Roche) included denaturation at 951C for 10 min, followed by 40 cycles of 951C for 10 s, 681C for 10 s, and 721C for 40 s. After each cycle, the PCR product was quantified. Finally, the temperature was kept at 681C for 1 min, then increased by 0.21C/s to 961C to analyse the melting curve. The primer sequences were as follows: Cdc25A, 5 0 -ACCGTCACTATG-GACCAGC-3 0 (sense) and 5 0 -TTCAGAGCTGGACTACA-TCC-3 0 (antisense) (Wu et al., 1998) HME1 in four or five dilutions from 1 : 1 to 1 : 64 or 1 : 256, which were used to generate a standard curve by automated analysis, and cDNA of all other cell lines in dilutions fitting into this standard curve. To confirm product purity, melting curves were checked, in some cases complemented by 1% agarose gel electrophoresis.
